phosphorylethanolamine and niacinamide

phosphorylethanolamine has been researched along with niacinamide in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Johne, A; Massimini, G; Scheible, H; Udvaros, I; von Richter, O	1
Johne, A; Kraetzer, F; Marx, A; Scheible, H; Wimmer, E	1

Trials

2 trial(s) available for phosphorylethanolamine and niacinamide

Article	Year
Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. British journal of clinical pharmacology, 2016, Volume: 82, Issue:6 Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Carbon Radioisotopes; Ethanolamines; Feces; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Metabolic Clearance Rate; Neoplasms; Niacinamide	2016
Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors. Drug metabolism and disposition: the biological fate of chemicals, 2017, Volume: 45, Issue:2 Topics: Adolescent; Adult; Aged; Biotransformation; Ethanolamines; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Middle Aged; Neoplasms; Niacinamide; Protein Kinase Inhibitors; Tissue Distribution; Young Adult	2017

Article

Year

Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.

British journal of clinical pharmacology, 2016, Volume: 82, Issue:6

Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Carbon Radioisotopes; Ethanolamines; Feces; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Metabolic Clearance Rate; Neoplasms; Niacinamide

2016

Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.

Drug metabolism and disposition: the biological fate of chemicals, 2017, Volume: 45, Issue:2

Topics: Adolescent; Adult; Aged; Biotransformation; Ethanolamines; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Middle Aged; Neoplasms; Niacinamide; Protein Kinase Inhibitors; Tissue Distribution; Young Adult

2017